<DOC>
	<DOCNO>NCT03022851</DOCNO>
	<brief_summary>This study aim investigate safety efficacy Occlutech® AFR device patient severe pulmonary hypertension ( PH ) .</brief_summary>
	<brief_title>The Prophet Trial - Pilot Study Assess Safety Efficacy Novel Atrial Flow Regulator ( AFR ) Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Age ≥ 6 year . Patient consent participation Patient agree comply followup schedule Right heart failure , chronic clinically severe Syncope due acute Pulmonary Hypertension episodes Severe pulmonary hypertension evident echocardiography catheterisation Patient successful ballon atrial septostomy ( BAS ) procedure stable hemodynamic state , assess investigator Local generalize sepsis acute infection ( ) Thrombophilic coagulation disorder Allergy nickel and/or titanium and/or nickel/titaniumbased material Allergy antiplatelet , coagulant , thrombotic therapy Intolerance contrast agent Participation medical trial shorter 30 day intend AFR implantation procedure Pregnancy ( assessed patient child bear potential urine dip stick ) Occluded inferior vena cava access Previous Atrial septum defect ( ASD ) / Patent Foramen Ovale ( PFO ) closure device place Intracardiac thrombus</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>